Dinesh V Ph D Patel

CEO Dinesh Patel exercised options and sold all 75,000 shares same-day for $7.5M, offsetting his stock position while stock trades near 52-week highs.

Dinesh Patel, the company's President and CEO, executed a textbook option exercise-and-sell on the same day: acquiring 75,000 shares through a stock option exercise and immediately liquidating the entire position. The combined transactions netted approximately $5.9M in proceeds after acquisition costs. This is the 19th open-market sale Patel has executed in the past three years, continuing a persistent selling pattern with no open-market purchases during that same window. His prior sales at this company show mixed timing: four of his five most recent exits at PTGX were poorly timed (the stock rose afterward), while one was well-timed (the stock fell). The current sale occurs while the stock trades near its 52-week high following a sharp rally over the prior three months, though the company's fundamentals remain stressed—it is unprofitable with significant revenue contraction. The exercise-and-sell structure is routine for options management, but the consistent avoidance of open-market purchases and the heavily tilted selling track record warrant noting.

CEO Patel sold 54,700 shares at $101.00 across 2 transactions ($5.5M) as stock nears 52-week high of $104.31.

Dinesh V Patel, President and CEO, executed 2 separate sales totaling 54,700 shares for $5,524,700.00 on March 24–25, 2026, reducing his holdings by 9.4% from 579,638 to 524,938 shares. The transactions occurred at $101.00 per share while the stock currently trades at $104.31, near its 52-week high of $104.31, in the context of a 30-day gain of +20.5% and 90-day gain of +17.4%. At PTGX specifically, Patel's 5 prior sales show inconsistent outcomes: 3 posted 30-day gains ranging +0.7% to +6.2%, while 1 posted a 30-day loss of -2.2%, with no 90-day outcomes yet measurable. The underlying company reported quarterly revenue of $4,712,000.00 with a net loss of $-39,339,000.00, annual revenue contraction of -89.4%, and an unprofitable fiscal year, alongside a market cap of $6,655,887,165.96. The CEO's sale comes at elevated valuation (stock at 52-week high) within a fundamentally challenged context (deep losses, revenue collapse).

CEO Dinesh Patel sold 48.3K shares for $4.1M (avg $84.18) in 4 transactions Jan 23-27

Dinesh Patel, President and CEO of Protagonist Therapeutics, executed 4 separate sales totaling 48,273 shares for $4,063,743.02 between January 23–27, reducing his holdings from 622.8K to 574.5K shares (-7.8%). The blended average sale price of $84.18 sits within the 52-week range and near the current price of $83.08, with no timing signal from the stock's -6.4% recent decline. His prior trades at PTGX show a 0% well-timed rate at 90 days—all four prior sales were followed by stock appreciation ranging from +35.1% to +41.3%—suggesting consistent poor timing in identifying downturns. The company operates at substantial net losses (-$39.3M latest quarter) despite explosive 624.1% annual revenue growth, and the elevated P/E of 113.81 reflects valuation risk; CEO liquidity at these price levels warrants investor scrutiny of fundamentals and near-term catalysts.

CEO Patel sells 34,438 PTGX shares at $82.48; stock now $83.89; prior 5 trades at ticker poorly timed (avg +12.6% 90d returns).

PATEL DINESH V PH D, President and CEO, sold 34,438 shares valued at $2,840,446.24 on 2026-01-20 at $82.48 per share, reducing holdings to 580,505 shares (a -5.6% reduction). At current price of $83.89, the sale price was 1.7% below market, placing the trade in the middle of the 52-week range ($35.09–$95.35) and 12.0% below the 52-week high. The CEO's prior five open-market sales at PTGX show a consistent pattern of poor timing: all five generated positive 90-day returns averaging +12.6%, meaning the stock rose after each sale—the insider sold before gains materialized. Only 1 of 5 prior PTGX trades achieved a negative 90-day return (well-timed for a seller). His cross-ticker track record shows 10 prior sells with a 30% well-timed rate (below-average precision), but within PTGX specifically the pattern is stark: four consecutive sales in July 2025 all achieved returns exceeding +1.8% in 30 days and +35% or more at 90 days. The current sale at a price below yesterday's close continues a pattern of liquidity events that have preceded subsequent strength in the stock rather than providing a hedge against decline.

CEO Dinesh Patel sold 10,415 shares of PTGX at $54.78, continuing pattern of recent sales; stock now $56.26.

Dinesh Patel, President and CEO, sold 10,415 shares (10.4K shares) at $54.78 for $570,533.70 ($570.5K), reducing his holdings from 531,018 shares (531.0K shares) to 520,603 shares (520.6K shares), a -2.0% reduction. This sale on 2025-07-25 is the third consecutive daily sale, following sales on 2025-07-23 and 2025-07-22, signaling a coordinated reduction phase. At the ticker-specific level, Patel's two prior measurable PTGX sales (2024-11-26 and 2024-11-25) produced 90-day returns of -22.2% and -17.5%, demonstrating well-timed sales where the stock declined after his exits. The current stock price of $56.26 is -5.9% from its 52-week high of $59.76, suggesting the window of opportunity for sales at elevated levels may be narrowing. Despite strong 90-day momentum (+23.3%) and annual revenue growth of +624.1%, the company is unprofitable with net income of $-11.7M on $28.3M quarterly revenue, a profile requiring ongoing scrutiny.

CEO Dinesh Patel sells 52,444 shares at $54.92 avg for $2.88M; 3 of 5 prior PTGX sells were well-timed (90d declines), but stock up 20.8% in 90 days

PATEL DINESH V PH D (President and CEO) executed 3 separate sales totaling 52,444 shares for $2,880,043.79, bringing holdings from 583,462 to 531,018 shares. The sales occurred at a blended average price of $54.92, near the 52-week high of $59.76. Notably, his prior PTGX trade history shows a 60% well-timed rate at the 90-day mark (3 of 5 prior sells preceded declines), suggesting pattern-based execution discipline; however, the current 90-day price action (+20.8%) runs counter to this historical timing strength. The stock trades at elevated P/E of 59.55 with recent quarterly revenue of $28,321,000.00 and net income of negative $-11,655,000.00, indicating a high-valuation, pre-profitability growth story where insider liquidity events warrant close observation.

PTGX CEO Dinesh Patel sells 100,000 shares (19.7% of holdings) for $4.7M at blended avg $46.81

CEO Dinesh Patel executed 2 separate sales totaling 100,000 shares for $4,680,749.20 on 2024-11-25 and 2024-11-26, reducing his holdings from 508.5K to 408.5K shares. The sales occurred near the 52-week high ($48.43), with transaction prices of $46.96 and $46.25 respectively. Protagonist is posting strong annual revenue growth of +125.7% but remains unprofitable with net income of $-33,210,000.00 on quarterly revenue of $4,675,000.00; at these scale metrics, profitability trajectory is material to valuation. His prior 4 sales at PTGX showed mixed 90-day timing (only 1 well-timed of 4), with the most recent June 2024 sale followed by -4.2% 30-day return but +19.4% 90-day return, suggesting prior sells have not reliably preceded price declines at this ticker.